Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Techne to Acquire Swiss Spatial Biology Firm Lunaphore

NEW YORK – Bio-Techne announced on Thursday that it is acquiring Swiss spatial biology firm Lunaphore for an undisclosed amount. 

Bio-Techne expects the acquisition to close in the first quarter of its fiscal year 2024, it said in a statement. Tolochenaz, Switzerland-based Lunaphore offers fully automated spatial biology products, including its Comet end-to-end platform that integrates staining, imaging, and image pre-processing steps into a high-throughput instrument. The instrument is designed for use with standard pathology slides and allows for the analysis of 40 different spatial biomarkers per sample in each run, Bio-Techne said.

According to Minneapolis-based Bio-Techne, Lunaphore's technology aids in the identification of clinically relevant biomarkers to support the development of diagnostics tools, streamline clinical trials, and improve patient outcomes. 

In April, the two firms announced a strategic partnership to develop a spatial multiomic workflow using the Comet instrument and Lunaphore's Spyre antibody panels with Bio-Techne's RNAscope HiPlex technology. The workflow will enable simultaneous hyperplex detection of protein and RNA biomarkers on the same slide at single-cell resolution, Bio-Techne said.

"Lunaphore is very complementary to Bio-Techne's leading spatial biology franchise, as Comet delivers an automation platform for our RNAscope assays, and we leverage our global commercial team to penetrate this rapidly growing market," Bio-Techne President and CEO Chuck Kummeth said in a statement. 

"Bio-Techne's global reach and commercial and operational excellence will enable Lunaphore to accelerate its penetration into the high-growth spatial biology market," Lunaphore CEO Ata Tuna Ciftlik said in a statement. 

The Scan

Cystatin C Plays Role in Immunosuppression, Cancer Immunotherapy Failure, Study Finds

A study in Cell Genomics provides insight into how glucocorticoids can lead to cancer immunotherapy failure via cystatin C production.

Aging, Species Lifespan Gene Expression Signatures Overlap

An Osaka Metropolitan University team reports in Nucleic Acids Research that transcriptional signatures of aging and maximum lifespan have similarities.

Splicing Subgroup Provides Protocols for Evaluating Splicing Variant Data

The group presents their approach on how to apply evidence codes to splicing predictions and other data in the American Journal of Human Genetics.

Single-Cell Transcriptomic Atlas of Mouse Cochlea to Aid Treatment Development

Researchers in PNAS conducted single-cell and single-nuclear sequencing of about 120,000 cells at three key timepoints in cochlear development to generate a transcriptomic atlas.